HSPG2 (P98160) variants and mutations
HSPG2 (also known as P98160) is a human protein-coding gene encoding a basement membrane-specific heparan sulfate proteoglycan core protein. Its annotated function is integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It…. It is annotated at the secreted, extracellular space, extracellular matrix, basement membrane. This analysis covers 5,741 HSPG2 variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes Schwartz-Jampel syndrome, Dyssegmental dysplasia, Silverman-Handmaker type, and Silverman-Handmaker type dyssegmental dysplasia. Example HSPG2 variants include M1T, M1V, and G2R.
Variant analysis overview
- Gene: HSPG2
- Protein: P98160
- UniProt accession: P98160
- Organism: Homo sapiens
- Variants analyzed: 5741
- Variant scope: all variants
- Completed: 2026-08-28
Variant and mutation evidence
- Variant composition: 5,458 unspecified-consequence records; 3 stop lost; 89 synonymous variants; 10 stop-gained variants; 158 missense variants; 15 frameshift variants; 2 in-frame insertions; 2 in-frame deletions; 4 splice-region variants; 3 substitution
- Prediction scores: 4,518 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Schwartz-Jampel syndrome, Dyssegmental dysplasia, Silverman-Handmaker type, Silverman-Handmaker type dyssegmental dysplasia, atrial fibrillation, COVID-19, dengue disease, AL amyloidosis, aortic stenosis, atrial flutter, chronic obstructive pulmonary disease, cardiac arrhythmia, cataract.
Protein structure and variant hotspots
- Protein features: 51 domains; 4 binding sites; 18 post-translational modification sites.
- Structural context: 5,414 variants have structural context.
- PTM context: 25 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable HSPG2 variants
Examples include M1T, M1V, G2R, W3C, W3G, W3L, W3S, R4W. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs2152809609, ClinGen CA338910129, ClinVar RCV003712957, MetaLR 0.44, MetaSVM -0.15, Uncertain significance, not provided
- M1V (p.Met1Val), rs2152809610, ClinGen CA338910133, ClinVar RCV001376032, MetaLR 0.34, MetaSVM -0.42, Uncertain significance, Schwartz-Jampel syndrome
- G2R (p.Gly2Arg), TOPMed rs1353819642, gnomAD rs1353819642, REVEL 0.20, CADD 22.70
- W3C (p.Trp3Cys), Ensembl rs1208982829, REVEL 0.09, CADD 22.40
- W3G (p.Trp3Gly), Ensembl rs1569769002, REVEL 0.05, CADD 20.60
- W3L (p.Trp3Leu), TOPMed rs1178320431, gnomAD rs1178320431, REVEL 0.08, CADD 11.20
- W3S (p.Trp3Ser), TOPMed rs1178320431, gnomAD rs1178320431
- R4W (p.Arg4Trp), gnomAD rs1470182358, REVEL 0.26, CADD 23.40
- A5V (p.Ala5Val), gnomAD rs1428357947, REVEL 0.25, CADD 23.00
- A6V (p.Ala6Val), gnomAD rs1198890268, REVEL 0.07, CADD 14.00
- G7D (p.Gly7Asp), rs2152809591, ClinGen CA338910046, ClinVar RCV002705230, ClinVar RCV004983087, REVEL 0.28, CADD 16.30, Uncertain significance, not provided; Inborn genetic diseases
- G7S (p.Gly7Ser), TOPMed rs1644513343, REVEL 0.14, CADD 10.10
- G7V (p.Gly7Val), rs2152809591, ClinGen CA338910042, ClinVar RCV003017760, Ensembl rs2152809591, REVEL 0.29, CADD 14.90, Uncertain significance, not provided
- A8E (p.Ala8Glu), rs1431679446, ClinGen CA338910035, ClinVar RCV001954199, ClinVar RCV005854139, REVEL 0.17, CADD 13.60, Uncertain significance, not provided; Inborn genetic diseases
- A8V (p.Ala8Val), TOPMed rs1431679446, gnomAD rs1431679446, REVEL 0.18, CADD 17.10, Uncertain significance
- L9P (p.Leu9Pro), TOPMed rs1289486927, REVEL 0.25, CADD 22.60
- L10M (p.Leu10Met), gnomAD rs1485822758, REVEL 0.13, CADD 13.90
- L10V (p.Leu10Val), gnomAD rs1485822758, REVEL 0.13, CADD 14.30
- L11R (p.Leu11Arg), TOPMed rs1400135884, REVEL 0.45, CADD 25.60
- A12P (p.Ala12Pro), 1000Genomes rs529434165, TOPMed rs529434165, gnomAD rs529434165, Uncertain significance
- A12T (p.Ala12Thr), rs529434165, ClinGen CA19121361, ClinVar RCV002786266, 1000Genomes rs529434165, REVEL 0.14, CADD 17.10, Uncertain significance, not provided
- A12V (p.Ala12Val), gnomAD rs1206136135, REVEL 0.14, CADD 19.60
- H16P (p.His16Pro), rs1644512300, ClinGen CA338909957, ClinVar RCV001906146, Ensembl rs1644512300, REVEL 0.37, CADD 21.60, Uncertain significance, not provided
- H16Y (p.His16Tyr), TOPMed rs1644512344, gnomAD rs1644512344, REVEL 0.20, CADD 15.70
- G17V (p.Gly17Val), Ensembl rs1644512136, REVEL 0.16, CADD 15.30
- G17W (p.Gly17Trp), Ensembl rs952850076, REVEL 0.18, CADD 23.30
- R18L (p.Arg18Leu), rs1644512070, ClinGen CA338909934, ClinVar RCV002044911, TOPMed rs1644512070, REVEL 0.13, CADD 18.50, Uncertain significance, not provided
- R18P (p.Arg18Pro), TOPMed rs1644512070, gnomAD rs1644512070, REVEL 0.36, CADD 20.90, Uncertain significance, not provided; Inborn genetic diseases
- A21G (p.Ala21Gly), TOPMed rs1381228735, gnomAD rs1381228735, REVEL 0.07, CADD 18.90
- A21S (p.Ala21Ser), gnomAD rs1295638426, REVEL 0.06, CADD 10.80
- A21V (p.Ala21Val), TOPMed rs1381228735, gnomAD rs1381228735, REVEL 0.08, CADD 19.20, Uncertain significance, Inborn genetic diseases
- V22E (p.Val22Glu), Ensembl rs1642744261, REVEL 0.46, CADD 23.40
- H24D (p.His24Asp), Ensembl rs1642743978
- H24R (p.His24Arg), ExAC rs756143996, gnomAD rs756143996, REVEL 0.05, CADD 5.08
- H24Y (p.His24Tyr), Ensembl rs1642743978
- L26* (p.Leu26Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R27M (p.Arg27Met), gnomAD rs1251697584, REVEL 0.20, CADD 21.10
- A28T (p.Ala28Thr), ExAC rs780574006, REVEL 0.23, CADD 24.10
- A28V (p.Ala28Val), rs754643779, ClinGen CA674035, ClinVar RCV001355248, ClinVar RCV002276710, REVEL 0.28, CADD 22.70, Conflicting interpretations, not provided; Connective tissue disorder
- Y29C (p.Tyr29Cys), rs1240459544, ClinGen CA338899414, ClinVar RCV001909208, ClinVar RCV004988885, REVEL 0.38, CADD 24.30, Uncertain significance, Inborn genetic diseases; not provided
- D30G (p.Asp30Gly), TOPMed rs1345713400
- D30H (p.Asp30His), ExAC rs762213934, TOPMed rs762213934, gnomAD rs762213934, REVEL 0.27, CADD 22.40
- D30N (p.Asp30Asn), ExAC rs762213934, TOPMed rs762213934, gnomAD rs762213934, REVEL 0.10, CADD 15.70
- D30Y (p.Asp30Tyr), ExAC rs762213934, TOPMed rs762213934, gnomAD rs762213934, REVEL 0.35, CADD 22.70
- G31D (p.Gly31Asp), gnomAD rs1358623149
- L32F (p.Leu32Phe), 1000Genomes rs185790675, ESP rs185790675, ExAC rs185790675, TOPMed rs185790675, REVEL 0.20, CADD 15.30, Likely benign
- S33C (p.Ser33Cys), gnomAD rs1241101897, REVEL 0.26, CADD 23.20
- S33P (p.Ser33Pro), NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- L34P (p.Leu34Pro), ESP rs371633219, ExAC rs371633219, TOPMed rs371633219, gnomAD rs371633219, REVEL 0.52, CADD 25.80, Uncertain significance, Inborn genetic diseases; not provided
- P35S (p.Pro35Ser), Ensembl rs1642740860, REVEL 0.28, CADD 24.30
- D37N (p.Asp37Asn), ExAC rs775580297, gnomAD rs775580297, REVEL 0.21, CADD 24.40
- I38M (p.Ile38Met), gnomAD rs1425446046, REVEL 0.04, CADD 0.00
- I38V (p.Ile38Val), rs772103808, ClinGen CA674027, ClinVar RCV001881990, ClinVar RCV002554163, REVEL 0.09, CADD 7.17, Uncertain significance, Inborn genetic diseases; not provided
- E39K (p.Glu39Lys), Ensembl rs1642740096, REVEL 0.28, CADD 23.90
- T40S (p.Thr40Ser), gnomAD rs761093699, REVEL 0.04, CADD 9.52
- V41I (p.Val41Ile), rs774480435, ClinGen CA674025, ClinVar RCV001870684, ClinVar RCV004040479, REVEL 0.05, CADD 5.36, Uncertain significance, Inborn genetic diseases; not provided
- T42A (p.Thr42Ala), Ensembl rs1642739349, REVEL 0.07, CADD 0.63
- A43T (p.Ala43Thr), ExAC rs770831434, TOPMed rs770831434, gnomAD rs770831434, REVEL 0.09, CADD 12.40
- A43V (p.Ala43Val), rs749042492, ClinGen CA674023, ClinVar RCV003300543, ExAC rs749042492, REVEL 0.07, CADD 0.50, Uncertain significance
- S44N (p.Ser44Asn), ExAC rs777743489, gnomAD rs777743489, REVEL 0.07, CADD 15.00
- M46I (p.Met46Ile), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- M46T (p.Met46Thr), ExAC rs769789769, TOPMed rs769789769, gnomAD rs769789769, REVEL 0.02, CADD 3.06
- R47C (p.Arg47Cys), 1000Genomes rs544234613, ExAC rs544234613, TOPMed rs544234613, gnomAD rs544234613, REVEL 0.12, CADD 18.50, Uncertain significance
- R47H (p.Arg47His), rs751202082, NCI-TCGA Cosmic COSV6597, ExAC rs751202082, TOPMed rs751202082, REVEL 0.07, CADD 16.20, Variant assessed as somatic; moderate impact.
- R47L (p.Arg47Leu), ExAC rs751202082, TOPMed rs751202082, gnomAD rs751202082, REVEL 0.05, CADD 15.90
- R47S (p.Arg47Ser), rs544234613, ClinGen CA674020, ClinVar RCV001976194, 1000Genomes rs544234613, REVEL 0.05, CADD 11.50, Uncertain significance, not provided
- T49A (p.Thr49Ala), rs532110530, ClinGen CA674015, ClinVar RCV003112574, 1000Genomes rs532110530, REVEL 0.05, CADD 18.90, Uncertain significance, not provided
- H50L (p.His50Leu), rs138518139, ClinGen CA674013, ClinVar RCV000414733, ClinVar RCV000757382, REVEL 0.08, CADD 8.00, Conflicting interpretations, not provided; not specified
- H50Q (p.His50Gln), Ensembl rs1642736610
- H50R (p.His50Arg), 1000Genomes rs138518139, ESP rs138518139, ExAC rs138518139, TOPMed rs138518139, REVEL 0.06, CADD 7.79, Likely benign
- H50Y (p.His50Tyr), gnomAD rs200821679, REVEL 0.06, CADD 0.07
- S51L (p.Ser51Leu), rs866719632, NCI-TCGA Cosmic COSV1010, gnomAD rs866719632, REVEL 0.14, CADD 15.40, Variant assessed as somatic; moderate impact.
- Y52* (p.Tyr52Ter), gnomAD rs1285368718, CADD 36.00
- D55A (p.Asp55Ala), ExAC rs753214888, gnomAD rs753214888, REVEL 0.45, CADD 23.40
- D55V (p.Asp55Val), ExAC rs753214888, gnomAD rs753214888
- D56E (p.Asp56Glu), Ensembl rs879195724
- D56G (p.Asp56Gly), Ensembl rs1642735834, REVEL 0.38, CADD 25.30
- D56N (p.Asp56Asn), Ensembl rs2152773281, REVEL 0.24, CADD 24.80
- E57K (p.Glu57Lys), gnomAD rs1642735487, REVEL 0.25, CADD 25.30
- D58E (p.Asp58Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- M59I (p.Met59Ile), TOPMed rs896551340, REVEL 0.10, CADD 15.00
- M59K (p.Met59Lys), TOPMed rs907399740, gnomAD rs907399740
- M59L (p.Met59Leu), ExAC rs772432762, gnomAD rs772432762, REVEL 0.04, CADD 1.12
- M59T (p.Met59Thr), TOPMed rs907399740, gnomAD rs907399740, REVEL 0.14, CADD 22.30
- M59V (p.Met59Val), ExAC rs772432762, gnomAD rs772432762, REVEL 0.14, CADD 5.32, Uncertain significance, Inborn genetic diseases
- L60V (p.Leu60Val), gnomAD rs1359909384
- A61T (p.Ala61Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S63G (p.Ser63Gly), TOPMed rs1642734493
- I64L (p.Ile64Leu), gnomAD rs1642734344, REVEL 0.08, CADD 8.60
- G66R (p.Gly66Arg), gnomAD rs1321699592, REVEL 0.33, CADD 22.60, Uncertain significance, not provided
- D67A (p.Asp67Ala), ESP rs370767149, ExAC rs370767149, TOPMed rs370767149, gnomAD rs370767149, REVEL 0.26, CADD 22.90
- D67N (p.Asp67Asn), Ensembl rs1557804264
- D68E (p.Asp68Glu), rs1869780, ClinGen CA673979, ClinVar RCV000375285, ClinVar RCV000889185, REVEL 0.06, CADD 1.05, Benign/Likely benign, not specified; not provided; Lethal Kniest-like syndrome
- D68H (p.Asp68His), ExAC rs746978748, TOPMed rs746978748, gnomAD rs746978748, REVEL 0.09, CADD 22.20, Uncertain significance
- D68N (p.Asp68Asn), rs746978748, ClinGen CA673980, ClinVar RCV001812454, ExAC rs746978748, REVEL 0.09, CADD 21.10, Uncertain significance, Inborn genetic diseases; not provided
- L69P (p.Leu69Pro), ExAC rs771639120, TOPMed rs771639120, gnomAD rs771639120, REVEL 0.28, CADD 20.40
- S71I (p.Ser71Ile), TOPMed rs781177979, Uncertain significance
- S71N (p.Ser71Asn), rs781177979, ClinGen CA338898697, ClinVar RCV001544516, TOPMed rs781177979, AlphaMissense 0.33, MetaLR 0.55, Uncertain significance, Schwartz-Jampel syndrome; Lethal Kniest-like syndrome
- S71T (p.Ser71Thr), TOPMed rs781177979, Uncertain significance
- G72V (p.Gly72Val), NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- D73E (p.Asp73Glu), ExAC rs745491060, TOPMed rs745491060, gnomAD rs745491060, REVEL 0.05, CADD 5.64
- D73N (p.Asp73Asn), TOPMed rs1442042874, gnomAD rs1442042874
- L74P (p.Leu74Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L74Q (p.Leu74Gln), TOPMed rs1642713998
- S76N (p.Ser76Asn), NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- S76R (p.Ser76Arg), ExAC rs748426323, TOPMed rs748426323, gnomAD rs748426323, REVEL 0.27, CADD 15.00, Likely benign
- G77A (p.Gly77Ala), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- G77E (p.Gly77Glu), ExAC rs781626223, gnomAD rs781626223, REVEL 0.21, CADD 20.20
- G77R (p.Gly77Arg), rs1033676362, NCI-TCGA Cosmic COSV1010, TOPMed rs1033676362, gnomAD rs1033676362, REVEL 0.23, CADD 22.10, Variant assessed as somatic; moderate impact.
- G77W (p.Gly77Trp), TOPMed rs1033676362, gnomAD rs1033676362
- D78N (p.Asp78Asn), TOPMed rs1453245298, Uncertain significance, Inborn genetic diseases; not provided
- D78Y (p.Asp78Tyr), TOPMed rs1453245298, REVEL 0.36, CADD 22.50, Uncertain significance, Inborn genetic diseases
- Q80H (p.Gln80His), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- M81I (p.Met81Ile), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6597, Variant assessed as somatic; moderate impact.
- M81T (p.Met81Thr), rs374829303, ClinGen CA673971, ClinVar RCV001765769, ClinVar RCV002538853, REVEL 0.26, CADD 20.50, Uncertain significance, Inborn genetic diseases; not provided
- V82L (p.Val82Leu), gnomAD rs1642712612, REVEL 0.25, CADD 31.00
- F84L (p.Phe84Leu), gnomAD rs1403555592
- F84S (p.Phe84Ser), TOPMed rs1046778509, gnomAD rs1046778509, REVEL 0.54, CADD 28.70
- R85* (p.Arg85Ter), rs747493127, ClinGen CA673952, NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6593, CADD 37.00, Pathogenic
- R85Q (p.Arg85Gln), ExAC rs780655396, TOPMed rs780655396, gnomAD rs780655396, REVEL 0.64, CADD 28.80
- A86V (p.Ala86Val), gnomAD rs1470632093, REVEL 0.51, CADD 28.40
- V88L (p.Val88Leu), TOPMed rs1642292808, REVEL 0.37, CADD 25.00
- V88M (p.Val88Met), NCI-TCGA TCGA novel, REVEL 0.41, CADD 25.60, Variant assessed as somatic; moderate impact.
- N89S (p.Asn89Ser), gnomAD rs1175912363
- F90L (p.Phe90Leu), Ensembl rs1642292393, REVEL 0.52, CADD 26.70
- T91A (p.Thr91Ala), TOPMed rs1642292245
- R92C (p.Arg92Cys), rs573015650, 1000Genomes rs573015650, ExAC rs573015650, TOPMed rs573015650, REVEL 0.22, CADD 23.00, Uncertain significance, Inborn genetic diseases
- R92H (p.Arg92His), rs554613529, ClinGen CA673949, NCI-TCGA Cosmic COSV6593, ClinVar RCV003202649, REVEL 0.17, CADD 3.55, Likely benign
- S93C (p.Ser93Cys), ExAC rs779062482, gnomAD rs779062482, REVEL 0.60, CADD 25.50
- I94M (p.Ile94Met), ExAC rs766053015, TOPMed rs766053015, gnomAD rs766053015, REVEL 0.07, CADD 4.13, Likely benign
- E95K (p.Glu95Lys), rs145704241, NCI-TCGA Cosmic COSV1010, 1000Genomes rs145704241, ESP rs145704241, REVEL 0.10, CADD 14.10, Uncertain significance
- E95Q (p.Glu95Gln), rs145704241, ClinGen CA673945, ClinVar RCV001002021, ClinVar RCV001342125, REVEL 0.08, AlphaMissense 0.07, Uncertain significance, not specified; Inborn genetic diseases; not provided
- E95V (p.Glu95Val), rs1056004722, ClinGen CA19087166, ClinVar RCV003087290, TOPMed rs1056004722, REVEL 0.12, CADD 16.20, Uncertain significance, not provided
- Y96H (p.Tyr96His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P98S (p.Pro98Ser), gnomAD rs1285994390, REVEL 0.14, AlphaMissense 0.24
- L100P (p.Leu100Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D102G (p.Asp102Gly), gnomAD rs1406421520, REVEL 0.45, CADD 24.40
- D102N (p.Asp102Asn), TOPMed rs1642290491, gnomAD rs1642290491, REVEL 0.13, CADD 19.10
- E107V (p.Glu107Val), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- F108L (p.Phe108Leu), 1000Genomes rs2501260, ESP rs2501260, ExAC rs2501260, TOPMed rs2501260, Benign
- R109* (p.Arg109Ter), ExAC rs759478340, gnomAD rs759478340, CADD 4.09
- R109G (p.Arg109Gly), ExAC rs759478340, gnomAD rs759478340, REVEL 0.25, AlphaMissense 0.55
- R109Q (p.Arg109Gln), rs773796176, NCI-TCGA Cosmic COSV6593, ExAC rs773796176, TOPMed rs773796176, REVEL 0.09, CADD 19.60, Variant assessed as somatic; moderate impact.
- E110D (p.Glu110Asp), Ensembl rs1642289325, REVEL 0.16, CADD 17.00
- V111G (p.Val111Gly), Ensembl rs1572380327
- V111L (p.Val111Leu), gnomAD rs1346960283, REVEL 0.04, CADD 21.50, Uncertain significance, Inborn genetic diseases
- E113K (p.Glu113Lys), rs144511257, ClinGen CA673937, ClinVar RCV001098550, ClinVar RCV001098551, REVEL 0.14, CADD 23.50, Uncertain significance, Inborn genetic diseases; Schwartz-Jampel syndrome; Chromosome 1p36 deletion synd
- V115A (p.Val115Ala), gnomAD rs1409493839, REVEL 0.52, CADD 24.60
- T118=, NCI-TCGA Cosmic COSV6593, Variant assessed as somatic; low impact.
- T118K (p.Thr118Lys), ExAC rs769350557, TOPMed rs769350557, gnomAD rs769350557, REVEL 0.11, CADD 19.10, Uncertain significance
- T118M (p.Thr118Met), rs769350557, ClinGen CA673936, ClinVar RCV003131200, ExAC rs769350557, REVEL 0.14, CADD 23.10, Uncertain significance
- E120K (p.Glu120Lys), TOPMed rs1642276654
- S121L (p.Ser121Leu), rs780963482, ClinGen CA673908, NCI-TCGA Cosmic COSV6593, ClinVar RCV001912673, REVEL 0.17, CADD 24.60, Uncertain significance, not provided
- E122D (p.Glu122Asp), NCI-TCGA TCGA novel, CADD 15.60, Variant assessed as somatic; moderate impact.
- E122Q (p.Glu122Gln), TOPMed rs1642276203
- Y123C (p.Tyr123Cys), Ensembl rs1572379616
- Y123N (p.Tyr123Asn), ExAC rs751331297, gnomAD rs751331297
- L124V (p.Leu124Val), 1000Genomes rs533716947, ExAC rs533716947, gnomAD rs533716947, REVEL 0.18, CADD 11.70
- K125E (p.Lys125Glu), ExAC rs758269640, gnomAD rs758269640, REVEL 0.34, CADD 28.90
- P127A (p.Pro127Ala), ExAC rs200220279, gnomAD rs200220279, CADD 17.60
- P127L (p.Pro127Leu), rs138549668, ClinGen CA673902, ClinVar RCV003131169, ESP rs138549668, REVEL 0.49, CADD 28.30, Uncertain significance, not provided
- P127R (p.Pro127Arg), ESP rs138549668, ExAC rs138549668, TOPMed rs138549668, gnomAD rs138549668, REVEL 0.59, CADD 26.90, Uncertain significance
- G128E (p.Gly128Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G128R (p.Gly128Arg), ESP rs145939703, ExAC rs145939703, TOPMed rs145939703, gnomAD rs145939703, REVEL 0.74, CADD 31.00
- D129G (p.Asp129Gly), ExAC rs767969810, TOPMed rs767969810, gnomAD rs767969810, REVEL 0.20, CADD 24.50, Uncertain significance, Inborn genetic diseases
- D129N (p.Asp129Asn), rs1388933414, TOPMed rs1388933414, gnomAD rs1388933414, REVEL 0.18, CADD 23.70, Uncertain significance
- D129Y (p.Asp129Tyr), TOPMed rs1388933414, gnomAD rs1388933414, REVEL 0.24, CADD 25.20, Uncertain significance, Schwartz-Jampel syndrome type 1; Lethal Kniest-like syndrome
- V131F (p.Val131Phe), ExAC rs759932952, TOPMed rs759932952, gnomAD rs759932952
- V131G (p.Val131Gly), gnomAD rs1642274242, REVEL 0.19, CADD 24.80
- V131I (p.Val131Ile), ExAC rs759932952, TOPMed rs759932952, gnomAD rs759932952, REVEL 0.14, CADD 17.90
- S133G (p.Ser133Gly), TOPMed rs1255929444, gnomAD rs1255929444
- S133N (p.Ser133Asn), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- S133R (p.Ser133Arg), TOPMed rs1255929444, gnomAD rs1255929444, REVEL 0.38, CADD 28.80
- V135M (p.Val135Met), rs199623122, ClinGen CA673897, ClinVar RCV002949739, ClinVar RCV005351056, REVEL 0.45, CADD 26.50, Uncertain significance, not provided; Inborn genetic diseases
- I137M (p.Ile137Met), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- K138Q (p.Lys138Gln), TOPMed rs1404564354, gnomAD rs1404564354, REVEL 0.42, CADD 32.00
- E139* (p.Glu139Ter), gnomAD rs1305074074, CADD 40.00
- E139V (p.Glu139Val), gnomAD rs1387834822, REVEL 0.25, CADD 24.30
- G142V (p.Gly142Val), gnomAD rs1390716354, REVEL 0.42, CADD 25.30
- W143* (p.Trp143Ter), rs1557793652, ClinGen CA338896514, ClinVar RCV000722257, TOPMed rs1557793652, Uncertain significance
Public HSPG2 analysis runs
- HSPG2 analysis run — HSPG2 (5,741 variants) — completed 2026-08-28